Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048945 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
NCT00048945: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00048945 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 820 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048945, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
Interventions
- DRUG PEGASYS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2002-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
What the finished NCT00048945 record still lists
NCT00048945 is an interventional study that assigns participants to a tested intervention. The registered 820 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which PEGASYS is the first listed.
NCT00048945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00048945 about?
NCT00048945 is a clinical study titled "Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B". The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
What is the current status of trial NCT00048945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2002-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00048945?
The interventions under investigation include: PEGASYS (DRUG).
Who is sponsoring clinical trial NCT00048945?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00048945's enrollment target sits among peer trials
820 404th of 2000 higher than 1,596 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia